Success Metrics

Completion Rate
0%(0/1)
Active Trials
1(33%)
Terminated
1(33%)

Phase Distribution

Ph phase_1
1
33%
Ph phase_2
1
33%

Phase Distribution

1

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 2Efficacy & side effects
1(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Terminated(1)
Other(1)

Detailed Status

Active, not recruiting1
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (50.0%)
Phase 21 (50.0%)

Trials by Status

active_not_recruiting133%
terminated133%
unknown133%

Recent Activity

1 active trials
Showing 3 of 3
active_not_recruiting

Registry on Percutaneous Electrochemotherapy

NCT05267080
terminatedphase_1

CORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19 (SARS-CoV-2)

NCT04627675
unknownphase_2

Electrochemotherapy on Head and Neck Cancer

NCT02549742

Clinical Trials (3)

Showing 3 of 3 trials
NCT05267080

Registry on Percutaneous Electrochemotherapy

Active Not Recruiting
NCT04627675Phase 1

CORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19 (SARS-CoV-2)

Terminated
NCT02549742Phase 2

Electrochemotherapy on Head and Neck Cancer

Unknown

All 3 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
3